Sekisui Chemical Co. has acquired EIDIA Co.

Lincoln International (“Lincoln”), a leading global mid-market investment bank, is pleased to announce that Sekisui Chemical Co., Ltd. (“Sekisui Chemical” or the “Company”) has agreed to acquire all issued shares of EIDIA Co., Ltd. (“EIDIA”), a wholly owned subsidiary of Eisai Co., Ltd. (“Eisai”). EIDIA manufactures, imports and sells clinical diagnostic reagents, clinical analyzers, laboratory reagents and physical and chemical equipment.

Sekisui Chemical considers its diagnostic system business segment to be one of its eight growing businesses that are driving growth throughout the Sekisui Chemical Group as part of the Company’s midterm management plan, “SHINKA!-Advance 2016”. Through this plan, Sekisui Chemical is focused on expanding its business into the life science fields, including its diagnostic system business, centering on Sekisui Medical Co., Ltd. (“Sekisui Medical”). Sekisui Medical has maintained a broad partnership with EIDIA, ranging from the joint development to the manufacture and sale of clinical diagnostic reagents.

The diagnostic reagents / analyzers market in Japan is approximately 500 billion yen. Globally, the market is approximately 6 trillion yen, highlighting the opportunity for market expansion concomitant with the economic growth of the emerging countries.

By incorporating EIDIA’s unique technologies, products and human resources, Sekisui Chemical aims to grow its life science fields into a global business with a significant presence, including an expanded portfolio of products and increased sales volume. Specifically, the acquisition of EIDIA is expected to result in the following:

• Expansion of the scale and content of the diagnostics system business
• Sales expansion through reinforcement of sales routes
• Reinforcement of R&D in new products and business lines

Lincoln acted as the exclusive financial advisor to Sekisui Chemical on this transaction.

Share: